Accessibility Menu
 

Oruka Therapeutics

(NASDAQ) ORKA

Current Price$53.42
Market Cap$2.64B
Since IPO (2024)+85%
5 Year+120%
1 Year+466%
1 Month+62%

Oruka Therapeutics Financials at a Glance

Market Cap

$2.64B

Revenue (TTM)

$0.00

Net Income (TTM)

$105.43M

EPS (TTM)

$-2.32

P/E Ratio

-23.00

Dividend

$0.00

Beta (Volatility)

0.72 (Low)

Price

$53.42

Volume

42,540

Open

$49.74

Previous Close

$53.42

Daily Range

$49.74 - $53.53

52-Week Range

$5.49 - $53.56

ORKA News

No articles available.

ORKA: Motley Fool Moneyball Superscore

63

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oruka Therapeutics

Industry

Biotechnology

Employees

68

CEO

Lawrence O. Klein, PhD

Headquarters

Menlo Park, MA, US

ORKA Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-25%

Return on Capital

-26%

Return on Assets

-22%

Earnings Yield

-4.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.64B

Shares Outstanding

49.54M

Volume

42.54K

Short Interest

0.00%

Avg. Volume

564.12K

Financials (TTM)

Gross Profit

$83.00K

Operating Income

$122.05M

EBITDA

$121.97M

Operating Cash Flow

$88.21M

Capital Expenditure

$209.00K

Free Cash Flow

$88.42M

Cash & ST Invst.

$337.04M

Total Debt

$1.93M

Oruka Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$28.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.64B

N/A

Market Cap/Employee

$94.33M

N/A

Employees

28

N/A

Net Income

$29.58M

+11.4%

EBITDA

$34.40M

+8.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$335.11M

-10.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.31M

+73.9%

Short Term Debt

$619.00K

+190.6%

Return on Assets

-21.58%

N/A

Return on Invested Capital

-25.79%

N/A

Free Cash Flow

$22.66M

-20.3%

Operating Cash Flow

$22.59M

-20.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KODKodiak Sciences Inc.
$40.63-5.09%
ANABAnaptysBio, Inc.
$57.68+1.67%
MNMDMind Medicine (MindMed) Inc.
$20.69+0.44%
OCSOculis Holding AG
$26.63-1.48%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%
NOKNokia
$8.82+0.07%

Questions About ORKA

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.